- Home
- Who we are
- Read, watch, listen
- Pharmacy
- Home Delivery
- Specialty Pharmacy
- Specialty Pharmacy - Patients
- Care Specialists Program
- Education Center
- Hypercholesterolemia
- Solid organ transplant
- Asthma
- Cystic fibrosis
- Hemophilia
- Hepatitis C
- Human Immunodeficiency Virus (HIV)
- Inflammatory bowel disease
- Osteoporosis
- Multiple Sclerosis
- Oncology (cancer)
- Psoriasis and psoriatic arthritis
- Rheumatoid arthritis
- Rights and responsibilities
- Overcome medicine challenges
- Specialty Pharmacy - Providers
- Patient Forms
- Careers
- Benefits
- Hub + Home
- Medication Therapy Management Internship
- Managed Care Residency Program
- Application Process
- Contact Us
- Newsroom Custom Content
- Prime Careers Spotlight
- Prime Careers Spotlight: September 2024
- Prime Careers Spotlight: October 2024
- Prime Careers Spotlight: November 2024
- Prime Careers Spotlight: April 2025
- Prime Careers Spotlight: May 2025
- Prime Careers Spotlight: June 2025
- Prime Careers Spotlight: July 2025
- Prime Careers Spotlight: August 2025
- Prime Careers Spotlight: September 2025
- Prime Careers Spotlight: October 2025
- Prime Careers Spotlight: November 2025
- Prime Careers Spotlight: December 2025
- Prime Careers Spotlight: January 2026
- Prime Careers Spotlight: February 2026
- Publications
- Quarterly Pipeline
- 2024-2025
- Quarterly Drug Pipeline: July 2024
- Quarterly Drug Pipeline: April 2024
- Quarterly Drug Pipeline: January 2024
- Quarterly Drug Pipeline Template 2.0
- Quarterly Drug Pipeline: October 2024
- Quarterly Drug Pipeline: January 2025
- Quarterly Drug Pipeline: April 2025
- Quarterly Drug Pipeline: July 2025
- Quarterly Drug Pipeline: October 2025
- Quarterly Drug Pipeline: January 2026
- Clinical Highlights
- Clinical Highlights: September 2024
- Clinical Highlights: October 2024
- Clinical Highlights: November 2024
- Clinical Highlights: December 2024
- Clinical Highlights: January 2025
- Clinical Highlights: February 2025
- Clinical Highlights: March 2025
- Clinical Highlights: April 2025
- Drug Approvals
- Drug Approvals Monthly Update: August 2024
- Drug Approvals Monthly Update: June 2024
- Drug Approvals Monthly Update: May 2024
- Drug Approvals Monthly Update: April 2024
- Drug Approvals Monthly Update: March 2024
- Drug Approvals Monthly Update: February 2024
- Drug Approvals Monthly Update: January 2024
- Drug Approvals Quarterly Update
- Drug Approvals Monthly Update: September 2024
- Drug Approvals: October 2024
- Drug Approvals: November 2024
- Drug Approvals: December 2024
- Drug Approvals: January 2025
- Drug Approvals: July 2024
- Drug Approvals: February 2025
- Drug Approvals: March 2025
- Drug Approvals: April 2025
- Quarterly Drug Approvals
- 2024-2025
- Quarterly Drug Approvals: October 2024
- Quarterly Drug Approvals: January 2025
- Quarterly Drug Approvals: April 2025
- Quarterly Drug Approvals: July 2025
- Quarterly Drug Approvals: October 2025
- Quarterly Drug Approvals: January 2026
- High Cost Therapy Profile
- 2024-2025
- High-Cost Therapy Profile: August 2024
- High-Cost Therapy Profile: June 2024
- High-Cost Therapy Profile: May
- High-Cost Therapy Profile: April
- High-Cost Therapy Profile: March
- High-Cost Therapy Profile: February
- High-Cost Therapy Profile: January
- High-Cost Therapy Profile: September 2024
- HIGH COST THERAPY PROFILE: OCT 2024
- High Cost Therapy Profile: November 2024
- High Cost Therapy Profile: December 2024
- High Cost Therapy Profile: January 2025
- High Cost Therapy Profile: February 2025
- High-Cost Therapy Profile: March 2025
- High Cost Therapy Profile: April 2025
- High-Cost Therapy Profile: May 2025
- High-Cost Therapy Profile: June 2025
- High-Cost Therapy Profile: July 2025
- High-Cost Therapy Profile: August 2025
- High-Cost Therapy Profile: September 2025
- High-Cost Therapy Profile: October 2025
- High-Cost Therapy Profile: November 2025
- High-Cost Therapy Profile: December 2025
- High-Cost Therapy Profile: January 2026
- High-Cost Therapy Profile: February 2026
- Oncology Insights
- 2024-2025
- Oncology Insights: Transformative treatment for small cell lung cancer
- Oncology Insights: First-in-class bladder cancer therapy and the Bacillus Calmette-Guérin (BCG) shortage
- Oncology Insights: October 2024
- Oncology Insights: December 2024
- Oncology Insights: 2024 Rewind
- Oncology Insights: February 2025
- Oncology Insights: March 2025
- Oncology Insights: April 2025
- Oncology Insights: May 2025
- Oncology Insights: June 2025
- Oncology Insights: July 2025
- Oncology Insights: August 2025
- Oncology Insights: September 2025
- Oncology Insights: October 2025
- Oncology Insights: November 2025
- Oncology Insights: December 2025
- Oncology Insights: January 2026
- Oncology Insights: February 2026
- FDA Decisions Expected
- 2024-2025
- FDA Decisions Expected: October 2024
- FDA Decisions Expected November 2024
- FDA Decisions Expected: December 2024
- FDA Decisions Expected: January 2025
- FDA Decisions Expected: February 2025
- FDA Decisions Expected: March 2025
- FDA Decisions Expected: April 2025
- FDA Decisions Expected: May 2025
- FDA Decisions Expected: June 2025
- FDA Decisions Expected: July 2025
- FDA Decisions Expected: August 2025
- FDA Decisions Expected: September2025
- FDA Decisions Expected: October 2025
- FDA Decisions Expected: November 2025
- FDA Decisions Expected: December 2025
- FDA Decisions Expected: January 2026
- FDA Decisions Expected: February 2026
- FDA Decisions Expected: March 2026
- Expert Clinical Network Insights
- 2024-2025
- Expert Clinical Network Insights: June 2024
- Expert Clinical Network Insights: April 2024
- Expert Clinical Network Insights: October 2024
- Expert Clinical Network Insights: December 2024
- Expert Clinical Network Insights: March 2025
- Expert Clinical Network Insights: August 2025
- Expert Clinical Network Insights: September 2025
- Expert Clinical Network Insights: December 2025
- Expert Clinical Network Insights: January 2026
- Prime Therapeutics Reports
- Fall 2024 Prime Therapeutics Report
- Spring 2024 Prime Therapeutics Report
- Summer 2024 Prime Therapeutics Report
- Spring 2025 Prime Therapeutics Report
- Summer 2025 Prime Therapeutics Report
- Fall 2025 Prime Therapeutics Report
- GLP-1
- 2024-2025
- GLP-1 Pipeline Update: November 2024
- GLP-1 Pipeline Update: November 2025
- The evolution of GLP-1s
- GLP-1 Pipeline Update: February 2025
- GLP-1 Pipeline Update: May 2025
- GLP-1 Pipeline Update: August 2025
- GLP-1 Pipeline Update: February 2026
- Clinical Insights
- 2022 Clinical Insights: Therapeutic Psychedlics: An emerging frontier in mental health
- 2022 Clinical Insights: Virtual reality: An emerging paradigm in healthcare
- Summer 2025 Issue: Clinical Insights – MASH
- Trending Topics & Drug Approvals
- 2024-2025
- Trending Topics & Drug Approvals: May 2025
- Trending Topics & Drug Approvals: June 2025
- Trending Topics & Drug Approvals: July 2025
- Trending Topics & Drug Approvals: August 2025
- Trending Topics & Drug Approvals: September 2025
- Trending Topics & Drug Approvals: November 2025
- Trending Topics & Drug Approvals: December 2025
- Trending Topics & Drug Approvals: January 2026
- Cell & Gene Pipeline Outlook
- Clinical News
- Clinical News
- Clinical News: August 2024
- Clinical News: June 2024
- Clinical News: May 2024
- Clinical News: April 2024
- Employer Market Insight Reports
- Pharmacy Trend Reports
- Medicaid Pharmacy Trend Reports
- 2024 Medical Pharmacy Trend Report
- 2025 Medical Pharmacy Trend Report
- Weight management: A holistic journey
- Climate change: An imprint on health
- Virtual reality: An emerging paradigm in health care
- Research
- AMCP Nexus 2025 research posters
- AMCP Nexus 2024 Research Posters
- 2024 AMCP Annual Meeting Research Posters
- Media
- Compliance / Legal
- Home
- Who we are
- Read, watch, listen
- Pharmacy
- Home Delivery
- Specialty Pharmacy
- Specialty Pharmacy - Patients
- Care Specialists Program
- Education Center
- Hypercholesterolemia
- Solid organ transplant
- Asthma
- Cystic fibrosis
- Hemophilia
- Hepatitis C
- Human Immunodeficiency Virus (HIV)
- Inflammatory bowel disease
- Osteoporosis
- Multiple Sclerosis
- Oncology (cancer)
- Psoriasis and psoriatic arthritis
- Rheumatoid arthritis
- Rights and responsibilities
- Overcome medicine challenges
- Specialty Pharmacy - Providers
- Patient Forms
- Careers
- Benefits
- Hub + Home
- Medication Therapy Management Internship
- Managed Care Residency Program
- Application Process
- Contact Us
- Newsroom Custom Content
- Prime Careers Spotlight
- Prime Careers Spotlight: September 2024
- Prime Careers Spotlight: October 2024
- Prime Careers Spotlight: November 2024
- Prime Careers Spotlight: April 2025
- Prime Careers Spotlight: May 2025
- Prime Careers Spotlight: June 2025
- Prime Careers Spotlight: July 2025
- Prime Careers Spotlight: August 2025
- Prime Careers Spotlight: September 2025
- Prime Careers Spotlight: October 2025
- Prime Careers Spotlight: November 2025
- Prime Careers Spotlight: December 2025
- Prime Careers Spotlight: January 2026
- Prime Careers Spotlight: February 2026
- Publications
- Quarterly Pipeline
- 2024-2025
- Quarterly Drug Pipeline: July 2024
- Quarterly Drug Pipeline: April 2024
- Quarterly Drug Pipeline: January 2024
- Quarterly Drug Pipeline Template 2.0
- Quarterly Drug Pipeline: October 2024
- Quarterly Drug Pipeline: January 2025
- Quarterly Drug Pipeline: April 2025
- Quarterly Drug Pipeline: July 2025
- Quarterly Drug Pipeline: October 2025
- Quarterly Drug Pipeline: January 2026
- Clinical Highlights
- Clinical Highlights: September 2024
- Clinical Highlights: October 2024
- Clinical Highlights: November 2024
- Clinical Highlights: December 2024
- Clinical Highlights: January 2025
- Clinical Highlights: February 2025
- Clinical Highlights: March 2025
- Clinical Highlights: April 2025
- Drug Approvals
- Drug Approvals Monthly Update: August 2024
- Drug Approvals Monthly Update: June 2024
- Drug Approvals Monthly Update: May 2024
- Drug Approvals Monthly Update: April 2024
- Drug Approvals Monthly Update: March 2024
- Drug Approvals Monthly Update: February 2024
- Drug Approvals Monthly Update: January 2024
- Drug Approvals Quarterly Update
- Drug Approvals Monthly Update: September 2024
- Drug Approvals: October 2024
- Drug Approvals: November 2024
- Drug Approvals: December 2024
- Drug Approvals: January 2025
- Drug Approvals: July 2024
- Drug Approvals: February 2025
- Drug Approvals: March 2025
- Drug Approvals: April 2025
- Quarterly Drug Approvals
- 2024-2025
- Quarterly Drug Approvals: October 2024
- Quarterly Drug Approvals: January 2025
- Quarterly Drug Approvals: April 2025
- Quarterly Drug Approvals: July 2025
- Quarterly Drug Approvals: October 2025
- Quarterly Drug Approvals: January 2026
- High Cost Therapy Profile
- 2024-2025
- High-Cost Therapy Profile: August 2024
- High-Cost Therapy Profile: June 2024
- High-Cost Therapy Profile: May
- High-Cost Therapy Profile: April
- High-Cost Therapy Profile: March
- High-Cost Therapy Profile: February
- High-Cost Therapy Profile: January
- High-Cost Therapy Profile: September 2024
- HIGH COST THERAPY PROFILE: OCT 2024
- High Cost Therapy Profile: November 2024
- High Cost Therapy Profile: December 2024
- High Cost Therapy Profile: January 2025
- High Cost Therapy Profile: February 2025
- High-Cost Therapy Profile: March 2025
- High Cost Therapy Profile: April 2025
- High-Cost Therapy Profile: May 2025
- High-Cost Therapy Profile: June 2025
- High-Cost Therapy Profile: July 2025
- High-Cost Therapy Profile: August 2025
- High-Cost Therapy Profile: September 2025
- High-Cost Therapy Profile: October 2025
- High-Cost Therapy Profile: November 2025
- High-Cost Therapy Profile: December 2025
- High-Cost Therapy Profile: January 2026
- High-Cost Therapy Profile: February 2026
- Oncology Insights
- 2024-2025
- Oncology Insights: Transformative treatment for small cell lung cancer
- Oncology Insights: First-in-class bladder cancer therapy and the Bacillus Calmette-Guérin (BCG) shortage
- Oncology Insights: October 2024
- Oncology Insights: December 2024
- Oncology Insights: 2024 Rewind
- Oncology Insights: February 2025
- Oncology Insights: March 2025
- Oncology Insights: April 2025
- Oncology Insights: May 2025
- Oncology Insights: June 2025
- Oncology Insights: July 2025
- Oncology Insights: August 2025
- Oncology Insights: September 2025
- Oncology Insights: October 2025
- Oncology Insights: November 2025
- Oncology Insights: December 2025
- Oncology Insights: January 2026
- Oncology Insights: February 2026
- FDA Decisions Expected
- 2024-2025
- FDA Decisions Expected: October 2024
- FDA Decisions Expected November 2024
- FDA Decisions Expected: December 2024
- FDA Decisions Expected: January 2025
- FDA Decisions Expected: February 2025
- FDA Decisions Expected: March 2025
- FDA Decisions Expected: April 2025
- FDA Decisions Expected: May 2025
- FDA Decisions Expected: June 2025
- FDA Decisions Expected: July 2025
- FDA Decisions Expected: August 2025
- FDA Decisions Expected: September2025
- FDA Decisions Expected: October 2025
- FDA Decisions Expected: November 2025
- FDA Decisions Expected: December 2025
- FDA Decisions Expected: January 2026
- FDA Decisions Expected: February 2026
- FDA Decisions Expected: March 2026
- Expert Clinical Network Insights
- 2024-2025
- Expert Clinical Network Insights: June 2024
- Expert Clinical Network Insights: April 2024
- Expert Clinical Network Insights: October 2024
- Expert Clinical Network Insights: December 2024
- Expert Clinical Network Insights: March 2025
- Expert Clinical Network Insights: August 2025
- Expert Clinical Network Insights: September 2025
- Expert Clinical Network Insights: December 2025
- Expert Clinical Network Insights: January 2026
- Prime Therapeutics Reports
- Fall 2024 Prime Therapeutics Report
- Spring 2024 Prime Therapeutics Report
- Summer 2024 Prime Therapeutics Report
- Spring 2025 Prime Therapeutics Report
- Summer 2025 Prime Therapeutics Report
- Fall 2025 Prime Therapeutics Report
- GLP-1
- 2024-2025
- GLP-1 Pipeline Update: November 2024
- GLP-1 Pipeline Update: November 2025
- The evolution of GLP-1s
- GLP-1 Pipeline Update: February 2025
- GLP-1 Pipeline Update: May 2025
- GLP-1 Pipeline Update: August 2025
- GLP-1 Pipeline Update: February 2026
- Clinical Insights
- 2022 Clinical Insights: Therapeutic Psychedlics: An emerging frontier in mental health
- 2022 Clinical Insights: Virtual reality: An emerging paradigm in healthcare
- Summer 2025 Issue: Clinical Insights – MASH
- Trending Topics & Drug Approvals
- 2024-2025
- Trending Topics & Drug Approvals: May 2025
- Trending Topics & Drug Approvals: June 2025
- Trending Topics & Drug Approvals: July 2025
- Trending Topics & Drug Approvals: August 2025
- Trending Topics & Drug Approvals: September 2025
- Trending Topics & Drug Approvals: November 2025
- Trending Topics & Drug Approvals: December 2025
- Trending Topics & Drug Approvals: January 2026
- Cell & Gene Pipeline Outlook
- Clinical News
- Clinical News
- Clinical News: August 2024
- Clinical News: June 2024
- Clinical News: May 2024
- Clinical News: April 2024
- Employer Market Insight Reports
- Pharmacy Trend Reports
- Medicaid Pharmacy Trend Reports
- 2024 Medical Pharmacy Trend Report
- 2025 Medical Pharmacy Trend Report
- Weight management: A holistic journey
- Climate change: An imprint on health
- Virtual reality: An emerging paradigm in health care
- Research
- AMCP Nexus 2025 research posters
- AMCP Nexus 2024 Research Posters
- 2024 AMCP Annual Meeting Research Posters
- Media
- Compliance / Legal
Support members with autoimmune diseases
Learn more about autoimmune diseases
Autoimmune diseases happen when your immune system is overactive and can't tell the difference between your own cells and foreign cells, causing the body to mistakenly attack normal cells. There are more than 100 different types of autoimmune diseases (e.g., rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis).1
50M
As many as 50M people in the United States have an autoimmune disease, making it the third most prevalent disease category, surpassed only by cancer and heart disease.2
Many high-cost autoimmune drugs are covered under the medical benefit. However, management across both benefits is critical to understanding total cost of care and uncovering additional savings opportunities.3
The autoimmune drug category has 25+ specialty drugs, treating more than 10 conditions led by rheumatoid arthritis disease, dermatologic diseases and inflammatory bowel disease (IBD). Autoimmune drug category continues to lead all others despite recent biosimilar competition.3
Based on Prime’s real-world data, annual IBD autoimmune drug therapy adherence is 65%, and autoimmune drug costs account for 70% of the total cost of care.3
1 in 100
One in every 100 of Prime’s commercially insured members had an autoimmune drug claim in the most recent quarter.3
A comprehensive approach to savings
Clinical rigor
Help your members get the right treatments with comprehensive policies, proactive pipeline monitoring and rigorous utilization management (UM).
Lower-cost medications
Manage across benefits and direct members to clinically appropriate, lower-cost medications, in the right care setting.
Lowest net cost
Implement lowest-net-cost strategies like biosimilars and shifts to lower-cost sites of care when applicable.
Specialized pharmacists
Get support from specialized pharmacists who reach out to providers to optimize drug therapy and report savings back to you.
Choose what works best for you and your members
Footnotes
*All brand names are property of their respective owners.
**The programs listed are not available to all clients. Please check with your representative if you are interested in learning more.
1 Autoimmune disorders. (n.d.). Mount Sinai Health System. https://www.mountsinai.org/health-library/diseases-conditions/autoimmune-disorders
2 Autoimmune diseases. (n.d.). National Institute of Environmental Health Sciences. https://www.niehs.nih.gov/health/topics/conditions/autoimmune#:~:text=As%20many%20as%2050%20million,significant%20role%20in%20disease%20development
3 Internal analysis, 2024